Faron Pharmaceuticals - Innovative medical solutions (Part 2)

Yes, it is. If we had followed the original plan, then for the primary endpoint regarding OS, Bex + Aza versus Vene + Aza would have been compared at 20-30 percent. It just doesn’t add up.

5 Likes